TRIMTECH Therapeutics
To add a bio or update company history, please click update information.
News from TRIMTECH Therapeutics
TRIMTECH Therapeutics
23 Jun 2026
TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases
TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.
TRIMTECH Therapeutics
5 Mar 2025
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
TRIMTECH Therapeutics
- Life Sciences
- Cambridge, United Kingdom
- £35m
- trimtechtherapeutics.com
- Update Information
More venture news
- 18 Sept 2026
Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026
Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences - 15 Sept 2026
Magnitude BiosciencesMagnitude Biosciences raises £1.3m led by Northstar Ventures to run drug discovery screens in living nematode worms
EquityLife Sciences
